Amgen reported strong Q2 performance with significant sales growth in key products and announced the strategic acquisition of ChemoCentryx, enhancing its portfolio. Management's optimistic tone and positive guidance, despite some macro headwinds, suggest investor confidence. These factors are likely to drive the stock higher in the short term.

[1]